• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Immatics N.V.

    6/18/25 1:46:36 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMTX alert in real time by email
    6-K 1 dp230373_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

     

    June 18, 2025


    Commission File Number: 001-39363

     

    IMMATICS N.V.

     

     

    Paul-Ehrlich-Straße 15

    72076 Tübingen, Federal Republic of Germany

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F

    ☒

      Form 40-F

    ☐

     

     

     

     

     

    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    On June 18, 2025, Immatics N.V. (the “Company”) held its Annual General Meeting of Shareholders (the “AGM”). A copy of the minutes of the proceedings of the AGM is furnished as Exhibit 99.1 hereto. At the AGM, the shareholders approved each of the voting items on the agenda, including:

     

    ·Adoption of the statutory annual accounts for the financial year ended December 31, 2024

     

    ·Discharge from liability for the members of the Company’s board of directors with respect to the performance of their duties during the financial year ended December 31, 2024

     

    ·Reappointment of Mr. P.A. Chambré as non-executive director class II

     

    ·Reappointment of Ms. H.L. Mason as non-executive director class II

     

    ·Appointment of Dr. A.S. Reicin as non-executive director class II

     

    ·Extension of the authorisation of the Board to acquire ordinary shares or depositary receipts thereof

     

    ·Approval of the Company’s 2025 stock option and incentive plan

     

    ·Instruction to PricewaterhouseCoopers Accountants N.V. as auditor for the financial year ending December 31, 2025

     

    INCORPORATION BY REFERENCE

     

    This Report on Form 6-K (other than Exhibit 99.1 hereto) shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Nos. 333-249408, 333-265820 and 333-280935) and the registration statements on Form F-3 (Registration Nos. 333-240260, 333-274218 and 333-286151) of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    EXHIBIT INDEX

     

    Exhibit No. Description
    99.1 AGM Minutes

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      IMMATICS N.V.
    Date: June 18, 2025  
      By: /s/ Harpreet Singh
      Name: Harpreet Singh
      Title: Chief Executive Officer

     

     

    Get the next $IMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMTX

    DatePrice TargetRatingAnalyst
    5/28/2025$10.00Buy
    Deutsche Bank
    10/7/2024$19.00Overweight
    Piper Sandler
    11/2/2023Overweight
    Cantor Fitzgerald
    3/31/2023$12.00Buy
    Mizuho
    3/24/2023$16.00Buy
    Bryan Garnier
    7/15/2021$26.00 → $27.00Outperform
    SVB Leerink
    More analyst ratings